|
Outcomes
|
N Eval
|
Prob (95% CI)
|
|---|
|
Neutrophil engraftment
|
236
| |
|
1-year
| |
97 (94–99)%
|
|
2-year
| |
97 (94–99)%
|
|
Platelet recovery
|
218
| |
|
1-year
| |
91 (87–94)%
|
|
2-year
| |
91 (87–95)%
|
|
Acute GVHD (II-IV)
|
239
| |
|
180-day
| |
36 (30–42)%
|
|
Acute GVHD (III-IV)
|
229
| |
|
180-day
| |
12 (8–17)%
|
|
Chronic GVHD
|
230
| |
|
1-year
| |
49 (43–56)%
|
|
2-year
| |
58 (51–64)%
|
|
Extensive cGVHD
|
230
| |
|
1-year
| |
39 (33–46)%
|
|
2-year
| |
46 (39–53)%
|
|
GRFS
|
230
| |
|
1-year
| |
35 (29–41)%
|
|
2-year
| |
27 (21–33)%
|
|
NRM
|
249
| |
|
1-year
| |
19 (14–24)%
|
|
2-year
| |
25 (20–31)%
|
|
4-year
| |
30 (24–36)%
|
|
Progression/relapse
|
249
| |
|
1-year
| |
15 (11–20)%
|
|
2-year
| |
19 (15–25)%
|
|
4-year
| |
21 (16–27)%
|
|
PFS
|
249
| |
|
1-year
| |
66 (60–72)%
|
|
2-year
| |
56 (49–62)%
|
|
4-year
| |
47 (41–54)%
|
|
Overall survival
|
249
| |
|
1-year
| |
73 (68–79)%
|
|
2-year
| |
63 (56–69)%
|
|
4-year
| |
56 (49–63)%
|
- GVHD graft-versus-host disease, Prob probability, CI confidence interval, N number, NRM non-relapse mortality, PFS progression-free survival, GRFS GVHD free, relapse-free survival
- Probabilities of acute GVHD, chronic GVHD, treatment-related mortality and progression/relapse were calculated using the cumulative incidence estimate. Progression-free survival and overall survival was calculated using the Kaplan-Meier product limit estimate
- Univariate analysis of alternative donor sources is shown in Additional file 1 Table S6
